Is Bayer AG (OTCMKTS:BAYRY) Now a ‘Buy’? Why did HSBC Securities Upgrade The Stock?


Bayer AG (OTCMKTS:BAYRY) Stock Upgrade

Bayer AG (OTCMKTS:BAYRY)’s stock was increased to a solid “Buy” by investment analysts at HSBC Securities. BAYRY’s past “Hold” rating is has been discontinued by the brokerage firm.

From a total of 1 analysts covering Bayer AG (OTCMKTS:BAYRY) stock, 1 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. Bayer AG was the topic of 3 analyst reports since September 21, 2015 according to the firm StockzIntelligence Inc. Citigroup downgraded shares on December 2 to “Neutral” rating. Zacks downgraded BAYRY stock in a recent report from September 21 to “Sell” rating.

Approximately 17,651 shares of stock traded hands. Bayer AG (ADR) (OTCMKTS:BAYRY) has declined 13.79% since May 7, 2015 and is downtrending. It has underperformed by 11.86% the S&P500.

Bayer AG is a strategic management holding company. The company has a market cap of $105.06 billion. The Company’s business are organized into three subgroups: Bayer HealthCare, Bayer CropScience and Bayer MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. It has 26.09 P/E ratio. Bayer HealthCare researches, develops, makes and markets products to improve the health of people and animals.

According to Zacks Investment Research, “Bayer AG, best known for its flagship product, Bayer Aspirin, produces a broad range of health care, crop protection, polymer, and chemical products that help diagnose and treat diseases, purify water, preserve local landmarks, protect crops, advance automobile safety and durability, and improve people’s lives.” Get a free copy of the Zacks research report on Bayer AG (ADR) (BAYRY).